← back to search

Richard Marais

Cancer Research Center · GB
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Melanoma and MAPK Pathways, Cancer Genomics and Diagnostics, Protein Kinase Regulation and GTPase Signaling, and Cutaneous Melanoma Detection and Management.
h-index
98
citations
48,712
works
626
NIH funding
primary concept
Medicine
email

Recent publications

SOX2 confers tumour permissiveness in a specific skin progenitor population.
2026cited by 0position: contributordoi
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial
Nature Communications 2026cited by 0position: contributordoi
SOX2 empowers a rapid tumorigenic programme from the tumour-resistant population in the skin
2025cited by 0position: contributordoi
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Nature Medicine 2024cited by 118position: middledoi
The journey from melanocytes to melanoma.
2023cited by 120position: contributordoi
Functional classification of DDOST variants of uncertain clinical significance in congenital disorders of glycosylation.
2023cited by 4position: contributordoi
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
Nature Medicine 2022cited by 420position: middledoi
MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
2022cited by 17position: contributordoi
Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
2022cited by 17position: contributordoi
Melanoma models for the next generation of therapies
Cancer Cell 2021cited by 226position: middledoi
The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.
2021cited by 151position: contributordoi
Ultraviolet radiation drives mutations in a subset of mucosal melanomas.
2021cited by 26position: contributordoi
Molecular characterization of fast-growing melanomas
Journal of the American Academy of Dermatology 2021cited by 14position: middledoi
Sunglasses to hide behind may also prevent melanoma of the eyes.
2021cited by 7position: contributordoi
Map3k1 Loss Cooperates with Braf<sup>V600E</sup> to Drive Melanomagenesis.
2021cited by 3position: contributordoi
Author Correction: The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.
2021cited by 1position: contributordoi
MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSE
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 0position: middledoi
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
Nature Cancer 2020cited by 230position: lastdoi
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
2020cited by 187position: contributordoi
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma.
2020cited by 25position: contributordoi
Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma
ESMO Open 2020cited by 6position: lastdoi
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.
2019cited by 233position: contributordoi
Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
2019cited by 82position: contributordoi
So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.
2019cited by 50position: contributordoi
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanoma.
2019cited by 34position: contributordoi
Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
2019cited by 2position: contributordoi
Abstract 3994: Genomic characterization of melanoma in the elderly reveals molecular drivers of progression and prognosis associated with immunotherapy response
Cancer Research 2019cited by 0position: middledoi
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Clinical Cancer Research 2018cited by 360position: middledoi
MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma
Development 2017cited by 79position: middledoi
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
Annals of Oncology 2016cited by 93position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2019–2026)Amaya Virós · University of Manchester6 papers (2014–2021)Sara Valpione · University of Manchester6 papers (2020–2021)Paul Lorigan · Christie's5 papers (2020–2022)Eduardo Nagore · Universitat de València3 papers (2019–2021)Gabriela Gremel · University of Manchester3 papers (2020–2021)Piyushkumar A. Mundra · St Vincent's Clinic3 papers (2020–2021)Patricia P. Centeno · Cancer Research UK3 papers (2023–2026)Piyushkumar A. Mundra · University of Manchester3 papers (2020–2021)Caroline Gaudy‐Marqueste · Centre National de la Recherche Scientifique3 papers (2019–2021)Nathalie Dhomen · University of Manchester2 papers (2020–2020)Paul Lorigan · The Christie NHS Foundation Trust2 papers (2020–2020)Rajiv Kumar · National Remote Sensing Centre2 papers (2021–2021)Stephen Smith · Cambridge University Hospitals NHS Foundation Trust2 papers (2019–2021)Caroline Dive · University College London2 papers (2019–2026)Valeria Pavet · Cancer Research UK2 papers (2021–2022) · 2 papers (2019–2021)Marc-Henri Stern · Sorbonne Université2 papers (2019–2021)Luca G Campana · Manchester University NHS Foundation Trust2 papers (2021–2021)Dominic G. Rothwell · National Cancer Centre Singapore2 papers (2019–2026)